{
    "nctId": "NCT03783546",
    "briefTitle": "Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial",
    "officialTitle": "Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 84,
    "primaryOutcomeMeasure": "Change From Baseline in Mean Weekly HFS Score Between Acupuncture and Usual Care Arms at the End of Week 10",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* History of histologically or cytologically proven Stage I-III breast cancer with estrogen receptor positive with HER-2 positive or negative tumor;\n* Premenopausal or postmenopausal status;\n* Completed all primary chemotherapy and surgery;\n* Currently undergoing adjuvant hormonal therapy (e.g. Tamoxifen and/or Aromatase inhibitors) with or without ovarian function suppression for at least 4 weeks at study entry; the use of Trastuzumab after adjuvant chemotherapy is allowed;\n* Reported persistent hot flashes for at least 4 weeks AND more than 14 episodes of hot flashes per week (2 hot flashes per day) during the week prior to the study entry;\n* Age \u2265 18 years;\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n* Signed informed consent\n\nExclusion Criteria:\n\nUndergoing chemotherapy or planned surgery, chemotherapy, change doses and regimen of hormonal therapy during the study period;\n\n* Unstable cardiac disease or myocardial infarction within 6 months prior to study entry;\n* Uncontrolled seizure disorder or history of seizure;\n* Active clinically significant uncontrolled infection;\n* Use of acupuncture for hot flashes within 6 months prior to the study entry;\n* Uncontrolled major psychiatric disorders, such as major depression or psychosis;\n* Newly starting pharmacologic treatment of hot flashes such as selective serotonin reuptake inhibitors (SSRIs) and/or anti-convulsant for less than 4 weeks prior to study entry. Participants may continue with medications or therapies for the treatment of hot-flashes while participating in the study if the medication has been taking for more than 4 weeks prior to study entry AND the dose of the medication is going to be kept consistently during the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}